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Background: MicroRNAs (miRNAs) are small non-coding RNAs involved in the modulation of gene expression and
in the control of numerous cell functions. Alterations of miRNA patterns frequently occur in cancer and metabolic
disorders, including obesity. Recent studies showed remarkable stability of miRNAs in both plasma and serum
making them suitable as potential circulating biomarkers for a variety of diseases and conditions.
The aim of this study was to assess the profile of circulating miRNAs expressed in plasma samples of overweight or
obese (OW/Ob) and normal weight (NW) prepubertal children from a European cohort (www.ifamilystudy.eu). The
project, aimed to assess the determinants of eating behavior in children and adolescents of eight European
countries, is built on the IDEFICS cohort (www.ideficsstudy.eu), established in 2006. Among the participants of the
I.Family Italian Cohort, ten OW/Ob (age 10.7 ± 1.5 years, BMI 31.6 ± 4.3 kg/m2) and ten NW (age 10.5 ± 2.7 years, BMI
16.4 ± 1.7 kg/m2) children were selected for the study. Gene arrays were employed to differentially screen the
expression of 372 miRNAs in pooled plasma samples. Deregulated miRNAs (p < 0.05) were further validated in the
individual samples using a real-time PCR (RT-qPCR) approach.
Results: Using a significance threshold of p < 0.05 and a fold-change threshold of ± 4.0, we preliminarily identified in
the pooled samples eight miRNAs that differed between the OW/Ob and NW groups. The validation by RT-qPCR in the
individual plasma samples showed a twofold upregulation of miR-31-5p, a threefold upregulation of miR-2355-5p, and
a 0.5-fold downregulation of miR-206 in OW/Ob as compared with NW. The molecular functions of these differentially
expressed plasma miRNAs as well as their expected mRNA targets were predicted by bioinformatics tools.
Conclusions: This pilot study shows that three circulating miRNAs are differentially regulated in OW/Ob as compared
with NW children. Although causal pathways cannot be firmly inferred by these results, that deserve confirmation in
larger samples, it is conceivable that circulating miRNAs may be novel biomarkers of obesity and related metabolic
disturbances.
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The obesity epidemic represents a major health chal-
lenge worldwide since it is associated with severe ad-
verse consequences for human health [1–3]. Excess
energy intake and lack of physical activity are the main
factors that drive the development of obesity. Individual
traits, such as the genetic profile, likewise contribute to* Correspondence: piacomino@isa.cnr.it
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types [4–6].
Adipose tissue, the storage site of triglycerides, acts as
an endocrine organ contributing to regulate energy
homeostasis [7, 8]. Anomalous fat accumulation in obes-
ity increases the risk of severe diseases such as metabolic
syndrome, type 2 diabetes, atherosclerosis, and cancer
[9]. Evidence suggests that in obesity, adipose tissues
stay in a state of subclinical chronic inflammation [10]cle is distributed under the terms of the Creative Commons Attribution 4.0
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phages into adipose tissues [11]. Adipogenesis is tightly
controlled by a mixture regulatory signals including endo-
cellular transcription factors and circulating hormones
[12]. Additional regulators of adipogenesis also include
microRNAs (miRNAs) [13–17]. These small non-coding
RNAs, which have a length of only 20–24 nucleotides, are
involved in the modulation of gene expression and,
consequently, in the control of numerous cell functions
[18–20]. At present, more than 2.000 different miRNAs
have been described in humans and their number is still
increasing (miRBase) (http://www.mirbase.org). miRNAs
are important elements of the cell epigenetic machinery
that, opposing to the other known players of epigenetic
regulation (DNA methylation and post-translational his-
tone modifications), can affect gene expression by binding
to the 3′ untranslated sequence of a target messenger
RNA (mRNA) [21]. Each miRNA can target many
transcripts, and transcription levels of a gene may be
regulated by multiple miRNAs [21, 22]. Computational
and experimental analyses indicate that endogenous
miRNAs regulate the expression of up to 30 % of
mouse and human genes [23]. miRNAs have been
shown to be involved in fundamental cellular processes
including proliferation, differentiation, DNA repair,
apoptosis, and metabolism [24, 25].
As a consequence, remarkable evidence indicates that
dysregulation of miRNAs is causative and/or indicator of
a number of disease processes including cancer [26].
Altered circulating miRNA profiles have been linked to
numerous cardiometabolic diseases, including hyperten-
sion (let-7e), type 2 diabetes (miR-126), hepatic injury
(miR-122), and atherosclerosis (miR-223) [14].
The presence of extracellular circulating miRNAs in
blood and other biological fluids is well established
[27, 28], but the reason for the nuclease resistance of
miRNAs outside the cell remained unclear for a long
period [29]. The discovery that cell-free miRNAs are
detectable in serum and plasma and that their expres-
sion varies as a result of disease offers great potential
for the discovery of novel health/disease biomarkers
and candidate therapeutic targets [30].
Various miRNAs have been recognized to play a role
in adipogenesis [31]. Preliminary evidence showed that
some circulating miRNAs are associated with obesity
and related metabolic disturbances in adults as well as in
children (see [16, 32] for review).
The primary aim of our study was to identify circulat-
ing miRNAs potentially associated to early obesity via an
integrated study comprising miRNA signatures and
bioinformatic analyses in children participating to the
I.Family survey. Here, we present the results of a pilot
study on a relatively small sample of children belonging
to the Italian cohort of the I.Family survey.Results and discussion
Distinct miRNA expression in plasma of OW/Ob and NW
children
The present study was aimed to identify new insights
into the pathogenesis of childhood obesity according to
the experimental scheme reported in Fig. 1. The main
characteristics of the participants are described in
Table 1. As time saving and efficiency strategy, samples
from ten overweight or obese (OW/Ob) and ten normal
weight (NW) were analyzed as pools in triplicate by PCR
arrays.
The geometric mean Ct value of multiple selected
housekeeping genes was 26.13 for NW and 26.38 for
OW/Ob. Reverse transcription control average Ct (RTC)
was 20.68 for NW and 20.75 for OW/Ob. Absent calls
were 1.82 % for NW and 2.34 % for OW/Ob.
Using a significance threshold of p < 0.05 and a fold-
change threshold of ±4.0, we identified in the pooled
samples eight out of 372 total screened miRNAs that
differed between the OW/Ob and NW groups
(Table 2). A scatter plot (Fig. 2) shows the relative ex-
pression levels of miRNAs in OW/Ob vs. NW pooled
plasma samples.
The eight miRNAs found to be differentially expressed
in the pooled analysis were subsequently validated in
real-time PCR (RT-qPCR) as distinct assays performed
in triplicate in the 20 individual plasma samples. PCR
reference gene included the endogenous spike-in C.el-
miR-39-3p. As reported in Table 3, the differential
expression of three miRNAs was statistically confirmed
(p value <0.05): a twofold upregulation of miR-31-5p, a
threefold upregulation of miR-2355-5p, and a 0.5-fold
downregulation of miR-206 were observed in OW/Ob as
compared with NW.
miRNAs target prediction, KEGG pathway analysis
The specialized algorithm miRPath v2.0 [33] was used to
understand the molecular functions of deregulated
miRNAs and to predict their putative mRNA targets. To
recognize biologically relevant molecular networks and
pathways, we further explored miRNA targets by analyz-
ing molecular interactions on the comprehensive know-
ledge base including the Kyoto Encyclopedia of Genes
and Genomes (KEGG) [34] and Ingenuity Pathways
Analysis. Both IPA and KEGG technologies provided
hints for the functions of miRNAs.
Top pathways predicted to be actively regulated by
miRNAs were classified according to the KEGG func-
tional annotation (Table 4).
Results of mir-31-5p MiRPath analysis on experi-
mentally validated miRNA interactions (derived from
DIANA-TarBase v6.0) or predicted targets (provided
by the DIANA-microT-CDS algorithm) are reported
in Table 5.
Determine expressed miRNAs
Pooled samples miRNome profiling
Confirm differentially expressed miRNAs
Individual profiling of samples (that went into pools)
Screen only highly differentially and significantly expressed miRNAs
Functional analysis
Fig. 1 Experimental scheme
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following targets in the “fatty acid degradation” pathway:
(a) the enoyl-CoA hydratase, a key enzyme in the break-
down of fatty acids essential to metabolizing fatty acids to
produce both acetyl CoA and energy, and (b) the alcohol
dehydrogenase 1A (Additional file 1: Figure S1).
Among the top predicted targets of miR-31-5p, we
also identify the CCAAT-enhancer-binding protein-α
(C/EBPα), a main modulator of the expression of genes
involved in cell cycle regulation as well as adipocyte
functions during adipogenesis (Fig. 2).
As relevant miR-206 targets, we recognized the “insulin
signaling,” the “pentose phosphate” pathways, and theTable 1 Anthropometric and metabolic variables of the
individuals included in this study
Normal weight Overweight/Obese p
Sex (M/F) 5/5 6/4
Age (years) 10.50 ± 2.76 10.70 ± 1.57 n.s
BMI (kg/cm2) 16.45 ± 1.71 31.68 ± 4.32 <0.001
Trg (mg/dL) 53.80 ± 22.08 84.20 ± 30.01 0.02
TC (mg/dL) 146.80 ± 24.10 163.40 ± 33.87 n.s
HDL (mg/dL) 62.30 ± 12.33 52.10 ± 12.37 n.s
LDL (mg/dL) 77.60 ± 22.51 100.70 ± 30.57 n.s
Glu (mg/dL) 91 ± 6.16 94.6 ± 3.53 n.s
Value are mean ± standard deviation
n.s = not significantliver X receptor-α (LXRα), a ligand-dependent transcrip-
tion factor playing a relevant role in the metabolism and
homeostasis of lipids, cholesterol, bile acids, and steroid
hormones with a preeminent expression in the liver.
Further, we identified the oleoyl-ACP hydrolase, a
medium-chain acyl-[acyl-carrier-protein] hydrolase in
the “fatty acid biosynthesis” pathway as a target of miR-
2355 (p = 0.005).
Finally, the target prediction of concurrently deregu-
lated miRNAs gave evidence for the “Notch” signaling
(p = 0.0008) (Additional file 2: Figure S2) and theTable 2 Differential miRNA expression profile determined by
gene-arrays screening
miRNA Fold regulation
miR-26b-5p 25.3723 ↑
miR-31-5p 4.9499 ↑
miR-2355-5p 6.5216 ↑
miR-1231 −8.7217 ↓
miR-361-3p −4.8918 ↓
miR-136-5p −4.8356 ↓
miR-320a −9.9692 ↓
miR-206 −6.0515 ↓
miRNAs showing significant differences in expression levels between the
compared groups are reported. Analyses were generated setting the threshold
at ±4 and p value <0.05
up arrow = upregulated; down arrow = downregulated
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Fig. 2 Differential expression of circulating miRNAs in plasma. Comparisons of OW/Ob vs. NW circulating miRNA profiles. The expression levels
were queried by qPCR arrays. Means of each data point are presented as a scatter plot (n = 3 in each group). Selection threshold is ±4.0.
Upregulated miRNAs are marked red whereas downregulated miRNAs are marked green
Table 4 MiRPath analysis
KEGG pathway p value
Gap junction 1.13E-13
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 2.90E-05
Notch signaling pathway 0.0003
Regulation of actin cytoskeleton 0.0005
Dorso-ventral axis formation 0.0008
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ways (p = 2.905898 × 10−05) (Additional file 3: Figure S3).
Discussion
We identified three circulating miRNAs differentially
expressed in plasma samples of OW/Ob children. Bio-
informatic exploratory analysis predicted their involve-
ment in critical pathways including lipid metabolism and
adipocyte differentiation.Table 3 Differential miRNA profile confirmed by RT-qPCR
miRNA OW/Ob NW Fold
regulation
p
miR-31-5p 3.60 (3.42–3.97) 1.86 (0.47–2.40) 1.92 0.0003 ↑
miR-2355-5p 3.65 (2.52–5.35) 1.23 (0.21–1.78) 2.93 0.0166 ↑
miR-206 1.28 (0.63–1.83) 2.45 (1.29–4.92) 0.52 0.0461 ↓
Differential miRNAs were confirmed by RT-qPCR. Reported values are mean
(minimum-maximum). Fold regulation was expressed as fold change with
respect to non-obese controls. Reference included the endogenous spike-in
C.el-miR-39-3p
up arrow = upregulated; down arrow = downregulated
Bacterial invasion of epithelial cells 0.0009
Axon guidance 0.0026
Shigellosis 0.0200
Endocrine and other factor-regulated calcium reabsorption 0.0397
Glycosaminoglycan biosynthesis—heparan sulfate/heparin 0.0483
Pathways in cancer 0.0490
Thyroid cancer 0.0500
Target genes were classified according to KEGG functional annotations to
identify top pathways that were actively regulated by miRNAs. Merged p value
is extracted by combining calculated significance levels using Fisher’s
meta-analysis method
Table 5 miRPath analysis of Hsa-mir-31-5p interactions
(A) KEGG-predicted pathway derived from
DIANA-microT-CDS database
p value genes
Metabolism of xenobiotics by cytochrome P450 1.46E-07 3
Inositol phosphate metabolism 0.00442 4
Fatty acid metabolism 0.02773 2
(B) KEGG-predicted targets provided by the
DIANA-TarBase v6.0 database
p value genes
Regulation of actin cytoskeleton 6.24E-06 5
Bacterial invasion of epithelial cells 1.79E-05 3
Axon guidance 8.85E-05 3
Shigellosis 0.00062 2
Pathogenic Escherichia coli infection 0.00276 2
Chemokine signaling pathway 0.00653 3
Pertussis 0.00746 2
Hypertrophic cardiomyopathy (HCM) 0.00979 2
Dilated cardiomyopathy 0.01157 2
T cell receptor signaling pathway 0.01604 2
Leukocyte transendothelial migration 0.01604 2
Arrhythmogenic right ventricular cardiomyopathy
(ARVC)
0.01604 2
Dorso-ventral axis formation 0.03214 1
miRPath analysis of miR-31-5p (A) of predicted targets provided by the DIANA-
microT-CDS algorithm or (B) of experimentally validated miRNA interactions
derived from the DIANA-TarBase v6.0. Target pathways were classified
according to KEGG functional annotations
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cesses because it influences metabolism. In adipogenesis,
pluripotent adipose-derived mesenchymal stem cells dif-
ferentiate into adipocytes. This process is finely regu-
lated by both hormones and transcription factors in a
complex signaling network. A number of miRNAs and
their targets were recently identified to play regulatory
roles in adipocyte differentiation [35–37]. To date, up to
221 miRNAs have been found to be expressed or dysreg-
ulated in adipose tissue or adipocytes in mammals [16].
Differentiation from pre-adipocytes into mature adipo-
cytes is orchestrated by several transcription factors such
as peroxisome proliferator-activated receptor-γ (PPARγ)
and C/EBPs (C/EBPs). C/EBPβ and C/EBPδ are induced
by adipogenic stimuli and represent primary regulators
of adipogenesis. Targets of C/EBPβ and C/EBPδ are the
promoters of the genes encoding crucial adipogenic
factors as C/EBPα and PPARγ as well as the sterol
regulatory element-binding protein (SREBP1), the key
regulator of lipogenic genes. The protein encoded by the
C/EBPα intronless gene is a leucine zipper transcription
factor which can bind to specific promoters and en-
hancers as a homodimer or it can form heterodimers
with the related proteins C/EBPβ and C/EBPγ (Fig. 3).The C/EBPα has been shown to bind to the promoter
and to also modify the expression of the leptin gene that
plays a central role in body weight homeostasis. C/EBPα
is sufficient to trigger differentiation of pre-adipocytes
into mature adipocytes [38]. Peculiarly, PPARγ directly
triggers endogenous C/EBPα transcription. In turn, C/
EBPα activates the PPARγ gene through a positive feed-
back loop and thereby promotes adipogenesis [12]. Con-
currently, PPARγ and C/EBPα induce the expression of
genes that are involved in insulin sensitivity, lipogenesis,
and lipolysis and, ultimately, in terminal differentiation
and mature functions of adipocytes.
miR-31 directly targets C/EBPα transcript whose levels
are in vivo downregulated by miR-31 [37]. Notably,
miR-31 expression is inversely correlated with adipo-
genic differentiation status [39], and consequently, it
has a decisive anti-adipogenic function.
We found that miR-31 was significantly upregulated in
plasma of OW/Ob children identifying C/EBPα as a pri-
vileged target of miR-31. miR-31 upregulation may be
considered as an apparent contradiction, but it probably
reflects the well-established role of circulating miRNAs
as “endocrine signals.” The concept that miRNAs may
be transferred from donor to recipient cells is now well
established with the relevant implication that miRNAs
could affect gene expression distally, so acting as para-
crine or endocrine signaling molecules. Accordingly, a
panel of “endocrine miRNAs” released from fat cells that
may be used as a marker of disturbed adipose tissue
function has been characterized [16]. The idea that
miR-31 acts as an obesity controlling signal seems to
be supported by the literature. Actually, in analyzing
the expression of miRNAs in the livers of leptin-
deficient obese (ob/ob) mice compared to normal
C57BL/6 mice, Li et al. found that ob/ob mice exhibited
an upregulation of miR-31 [40], despite its well-
established anti-adipogenic role.
Computational prediction of miR-31 recognized
several targets in the “fatty acid degradation” pathway
(p = 0.027) (Additional file 1: Figure S1). Whether
miR-31 deregulation plays a causative role or is
merely an epiphenomenon in the etiology of obesity
still remains to be determined.
In this study, we also observed that miR-206 was sig-
nificantly downregulated in plasma of OW/Ob children.
miR-206 belongs to the cluster of the so-called myomiRs
and represents one of the most studied tissue-specific
miRNAs involved in skeletal muscle differentiation. Sev-
eral studies indicate that miR-206 plays a key role in the
growth and development of skeletal muscle, promoting
myogenic differentiation [41]. Moreover, it has been well
established that it is related to the pathogenesis of nu-
merous diseases including heart failure, chronic ob-
structive pulmonary disease, and Alzheimer’s disease
Fig. 3 C/EBPα, a key target. The C/EBPα intronless gene encodes a transcription factor containing a basic leucine zipper domain. The protein acts
in homodimers or heterodimers that recognize the CCAAT motifs in the promoters of target genes. Complexes modulate the expression of genes
involved in cell cycle regulation as well as adipocyte functions: during adipogenesis highly induced genes are synergistically controlled by both
PPARγ and C/EBPα
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of these diseases, miR-206 levels are downregulated,
which leads to the recognition of miRNA as a “disease-
avoiding” molecule. Moreover, miR-206 expression is
abundant in brown adipocytes but missing in white adi-
pocytes [42]. Remarkably, it has been shown that miR-
206 suppresses liver LXRα, a gene target of PPAR,
consequently inhibiting lipogenesis and controlling
lipid metabolism [43]. The insulin signaling pathway
(p = 0.01, 11 target genes) and the pentose phosphate
pathway (p = 0.01, 4 target genes) were also identified
as candidate targets of miR-206. Therefore, the re-
duced level of circulating miR-206 in OW/Ob chil-
dren may be either representative of a functional
decreased synthesis [42] or an epiphenomenon reflect-
ing the reduced relative skeletal muscle mass in the
OW/Ob group.
Among the top pathways that were predicted to be
targeted by the three differentially expressed miRNAs,
“Notch” signaling appears relevant (p = 0.0008, 5 target
genes, Additional file 2: Figure S2). Notch signaling rep-
resents a basic biological pathway primarily related to
cell communication and development with extensive in-
tegration and crosstalk with other signaling pathways.
Perturbations in this pathway have been linked to many
genetic disorders and cancers. Accordingly, the direct in-
volvement of Notch signaling has recently been demon-
strated in obesity and type 2 diabetes [44]: throughtranscriptional binding partners FoxO1 and Rbpj, Notch
activation enhances pathologic glucose output and fatty
liver in obese, in combination with a reduced Akt activa-
tion by insulin. Activation of the Notch pathway in
obesity results in heightened diabetes and fatty liver
production, as a consequence of an augmented lipo-
genesis that is not blocked despite the reduced insulin
signaling. Notably, blocking Notch signaling in mice
caused white fat cells to transform into beige fat con-
sequently reducing the risk of obesity and related
health problems [44].
While we recognize the limitations and the relative
reliability of our target prediction analyses, this
hypothesis-generating exercise suggested the involve-
ment of the detected miRNAs in metabolic relevant
pathways, to be obviously confirmed by larger and ad
hoc designed studies.
Our results confirm those of recent papers indicating
that circulating miRNAs are deregulated in obese chil-
dren [45] and are associated with obesity and lipid ab-
normalities in adolescents [46]. However, differentially
detected miRNA signals in refs. 46 and 47 are not con-
sistent with those identified in our study. Of note, all
these miRNAs are present in the 372 miRNA arrays we
used in our study but did not pass the threshold we set
to consider them as differentially expressed. A solid ex-
planation of these discrepancies is not at hand. Consid-
ering the rapidly changing scenario in this field, the
Iacomino et al. Genes & Nutrition  (2016) 11:7 Page 7 of 9interpretation and discussion of the inconsistent findings
regarding the association of circulating miRNAs with
obesity in children [45, 46] is far beyond the objective
of this study. However, recent reviews extensively
summarized potentiality, but also uncertainties, of the
role of extracellular miRNAs as potential regulators
and/or biomarkers of obesity and metabolic diseases
[16, 32]. In particular, the inconsistencies of the find-
ings may be ascribed to inter-population differences,
but even, and perhaps most likely, to methodological
differences in sampling, RNA isolation, detection, and
normalization [32]. The need for consistent analysis
strategies and quality control has been recently dis-
cussed [47].
Conclusions
This pilot study showed that three circulating miRNAs
are differentially regulated in OW/Ob as compared with
NW children. Although causal pathways cannot be
firmly inferred—but only suggested—by these prelimin-
ary results, that deserve confirmation in other popula-
tions, it is conceivable that circulating miRNAs may be
novel biomarkers of obesity and related metabolic
disturbances.
The planned completion of the miRNA studies in the
much larger sample of children from the eight European
countries participating to the I.Family project will cer-
tainly contribute to the ongoing debate whether circulat-
ing miRNAs play a role in disease pathogenesis, are
(early) indicators of a metabolic dysfunction, or both.
Methods
Study cohort
The I.Family project aimed to assess the determinants of
eating behavior in children and adolescents of eight
European countries and related health outcomes was
built on the IDEFICS cohort (http://www.ideficsstudy.eu),
established in 2006. We selected our sample among OW/
Ob and NW participants of the Italian cohort of the pro-
ject. The weight status of children was defined according
to age- and sex-specific BMI categories [48]. Ten OW/Ob
(four females and six males, age 10.7 ± 1.5 years, BMI
31.7 ± 4.3 kg/m2) and ten NW (five females and five males,
age 10.5 ± 2.7 years, BMI 16.4 ± 1.7 kg/m2) children were
included in the study.
The study protocol was approved by the local Ethics
Committee of the local Health Authority (ASL Avellino)
and informed written parental consent was obtained for
each participant.
Sample processing
Whole blood was collected according to the standard
operating procedures in BD Vacutainer® blood collection
tubes. The optimal approach for miRNA purificationfrom whole blood necessitates collecting fresh blood and
processes the sample as quickly as possible. Accordingly,
plasma was isolated by centrifugation at 1900×g for
10 min at 4 °C in an Eppendorf benchtop centrifuge
(Eppendorf, Germany), aliquoted into 1.5 mL Eppendorf
tubes, and promptly stored at −80 °C, in the absence of
freeze-thaw cycles, until processing.
miRNA extraction, reverse transcription, and pre-screening
Prior to miRNA extraction, spectrophotometry was car-
ried out on plasma samples to test for hemolysis by
measuring the absorbance of free hemoglobin at
414 nm; samples with OD414 greater than 0.2 were ex-
cluded from the study. RNA was extracted from both
plasma pooled samples and from individual plasma
samples using the commercial column-based system
miRNeasy serum/plasma Kit (Qiagen, Germany) accord-
ing to the manufacturer’s instructions with minor modi-
fications. Plasma was thawed on ice and spun for 10 min
at 13,000×g at 4 °C in an Eppendorf benchtop centrifuge
(Eppendorf, Germany) to pellet any debris. An aliquot of
200 μL of plasma was transferred to a new microcentri-
fuge tube and 800 μL of a Qiazol (Qiagen) mixture, con-
taining 1.25 μg/mL of MS2 bacteriophage RNA (Roche
Applied Science), was added to the sample. Caenorhab-
ditis elegans miR-39 (C.el-miR-39) was spiked into the
sample (5.6 × 108 molecules) before the extraction
process to assess RNA recovery. A rinse step (500 μL
Qiagen RPE buffer) was repeated two times. Total RNA
was eluted by adding 14 μL of RNase-free water to the
membrane of the column and incubating for 1 min be-
fore centrifugation at 13,000×g for 1 min at room
temperature. The obtained RNA was stored at −80 °C.
Complementary DNA (cDNA) was generated by
means of the miScript RTII kit (Qiagen), in HiSpec
Buffer with miRNA-specific stem-looped RT primers.
Nine microliters of isolated RNA were reverse tran-
scribed in 20-μL reactions according to the manufac-
turer’s recommendations. The obtained cDNA was
diluted 1:5.5 in RNase-free water. This procedure was
repeated three times. To identify hemolyzed samples,
the levels of miR-451, highly abundant in RBCs, were
preliminarily assessed in cDNA samples by qPCR.
Hemolyzed samples were excluded from the analysis.
Circulating miRNA profiling
Selected samples from ten OW/Ob and ten NW chil-
dren (Table 1) were pooled, and miRNAs were extracted
as described above. miRNA profiling was performed by
using the Serum and Plasma 384HC miScript miRNA
PCR Arrays (SABiosciences, Qiagen) to assess the ex-
pression of 372 miRNAs typically detectable in serum
and plasma. The SYBR green-based qPCR assay was per-
formed with cDNA (dil. 1:225) in 10-uL reaction volume
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(Applied Biosystems). Reaction conditions were as fol-
lows: 15 min at 95 °C and 40 cycles of 15 s at 94 °C, 30 s
at 60 °C, and 30 s at 72 °C with a set of technical controls
on each plate which included the spike-in control and
small non-coding RNAs (SNORDs) as reference genes.
References for data normalization included the spike-in
C.el-miR-39-3p, SNORD61, SNORD68, SNORD72,
SNORD95, and SNORD96A, which have been verified
to hold relatively stable expression levels across tis-
sues and cell types. Normalization of expression was
done using the geometric mean of the endogenous
controls. All assays were inspected for distinct melt-
ing curves, and the Tm was checked. The amplifica-
tion efficiency was also calculated. Ct values >35 were
considered as negative amplification. Data that did
not pass these criteria were omitted from further analysis.
The efficiency of reverse transcription was assessed with
miRTC.
Statistically significant deregulated miRNAs with a
fold-change ≥4.0 were selected and further validated by
individual microRNA assays (SABiosciences, Qiagen)
performed on the individual plasma samples of ten OW/
Ob and ten NW children, using the miScript SYBR
green PCR kit (Qiagen) according to the manufacturer’s
instructions. RT-qPCR was performed in triplicates
using the following conditions: 95 °C for 15 min,
followed by 40 cycles of 94 °C for 15 s, 55 °C for 30 s,
and 70 °C for 30 s. Relative miRNA levels were deter-
mined by the ΔΔCt method using the C.el-miR-39 as
endogenous normalizer.
Data analysis
On pooled samples, RT-qPCR quantifications were per-
formed by using SDS 2.3 (Life Technologies, USA) to
generate Ct values.
Gene Arrays data were organized in Excel (Microsoft),
and the integrated web-based software package for
miScript Arrays analysis was exploited. This software
performs quantification using the ΔΔCt method and in-
terpretation of the control assays. Tools are available at
the SABiosciences data analysis web portal.
Data on the individual samples are presented as the
average of at least three independent experiments ± s.e..
Data Assist 3.1 software packages (Life Technologies,
USA) were used to generate relative “fold-change”
values. Student’s t test, performed with the GraphPad
Prism 6 software, was used to determine the significance
of any difference in the levels of miRNA expression be-
tween NW and OW/Ob subjects with alpha <0.05.
Obesity-associated miRNAs were tested using the
well-established target prediction tool miRPath v2.0 [33].
miRPath achieves advanced analysis pipelines, such as
hierarchical clustering of miRNAs and pathways basedon the levels of their interactions. miRNA targets (in
CDS or 3′-UTR regions) were predicted by the DIANA-
microT-CDS algorithm or even experimentally validated
miRNA interactions derived from DIANA-TarBase v6.0.
Predicted and/or validated interactions were subse-
quently combined with merging and meta-analysis
algorithms.
All the predicted targets were further analyzed
through the use of Kyoto Encyclopedia of Genes and
Genomes (KEGG) [34] and QIAGEN’s Ingenuity®
Pathway Analysis (IPA®, QIAGEN Redwood City,
www.qiagen.com/ingenuity). IPA identified lists of
genes that satisfy specific biological criteria scoring these
genes towards pathways in the Ingenuity Knowledge Base
which embraces a large database of biological and chem-
ical relationships extracted from scientific literature.
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